Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.44 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769675 | 0.86 | CHUK (0.48) | RETCSF1REGFRAURKAAURKB | |
| SCHEMBL4764349 | 0.86 | EGFR (0.53) | CSF1REGFRKITAURKAAURKB | |
| SCHEMBL4770678 | 0.83 | KDR (0.59) | RETCSF1REGFRKITPIK3CG | |
| SCHEMBL4767215 | 0.83 | RET (0.52) | RETCSF1REGFRCHUKINSR | |
| SCHEMBL4764488 | 0.82 | PIK3CA (0.46) | RETEGFRKITPIP4K2APIK3CG | |
| SCHEMBL4764512 | 0.82 | PIK3CA (0.51) | RETCSF1REGFRKITINSR | |
| SCHEMBL4764299 | 0.81 | CSF1R (0.61) | RETCSF1REGFRKITTNKS | |
| SCHEMBL4770875 | 0.80 | CSF1R (0.52) | RETCSF1REGFRCHUKINSR | |
| SCHEMBL4764474 | 0.79 | CHUK (0.47) | RETCSF1REGFRAURKAAURKB | |
| SCHEMBL4764558 | 0.79 | EGFR (0.63) | CSF1REGFRAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | RET 2696/4885CSF1R 3024/4885EGFR 3391/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | RET 2836/4885CSF1R 3516/4885EGFR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.